Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AJMUC1 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Guangzhou Anjie Biomedical Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AJMUC1 CAR-T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target Mucin 1 (MUC1), a transmembrane glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial malignancies, including breast cancer. Developed by Sun Yat-sen Memorial Hospital at Sun Yat-sen University, this cell therapy involves the genetic modification of a patient's own T cells to express a CAR specific to the MUC1 antigen. Upon re-infusion, these engineered cells recognize and bind to MUC1-positive tumor cells, triggering T-cell activation and subsequent tumor cell lysis. The program is primarily being evaluated for safety, toxicity, and in vivo expansion in patients with MUC1-positive advanced, recurrent, or metastatic breast cancer who have failed standard treatments.
- Other names
- AJMUC1 CAR-TAJMUC-1 CAR-TAJMUC 1 CAR-TMUC1-targeted CAR-T cellsMUC-1-targeted CAR-T cellsMUC 1-targeted CAR-T cells
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on AJMUC1 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AJMUC1 CAR-T cells.